Chemistry:SRT-3025
From HandWiki
Short description: Organic compound, experimental pharmaceuticum
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C31H31N5O2S2 |
| Molar mass | 569.74 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
SRT-3025 is an experimental drug that was studied by Sirtris Pharmaceuticals as a small-molecule activator of the sirtuin subtype SIRT1. It has been investigated as a potential treatment for osteoporosis,[1][2][3][4][5] and anemia.[6][7]
See also
References
- ↑ "Angiotensin II induces mitochondrial oxidative stress and mtDNA damage in osteoblasts by inhibiting SIRT1–FoxO3a–MnSOD pathway". Biochemical and Biophysical Research Communications 455 (1–2): 113–8. December 2014. doi:10.1016/j.bbrc.2014.10.123. PMID 25450701.
- ↑ "The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells". PLOS ONE 10 (7): e0134391. 2015. doi:10.1371/journal.pone.0134391. PMID 26226624. Bibcode: 2015PLoSO..1034391G.
- ↑ "Sirtuin1 Suppresses Osteoclastogenesis by Deacetylating FoxOs". Molecular Endocrinology 29 (10): 1498–509. October 2015. doi:10.1210/me.2015-1133. PMID 26287518.
- ↑ "Drugs targeting SIRT1, a new generation of therapeutics for osteoporosis and other bone related disorders?". Pharmacological Research 143: 97–105. May 2019. doi:10.1016/j.phrs.2019.03.007. PMID 30862606.
- ↑ "Sirt1 Promotes a Thermogenic Gene Program in Bone Marrow Adipocytes: From Mice to (Wo)Men". Frontiers in Endocrinology 10: 126. 2019. doi:10.3389/fendo.2019.00126. PMID 30873124.
- ↑ "The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice". Stem Cell Research 15 (1): 130–40. July 2015. doi:10.1016/j.scr.2015.05.007. PMID 26046330.
- ↑ "Sirt1 in the Regulation of Interferon Gamma in Severe Aplastic Anemia". Acta Haematologica 142 (3): 142–148. 2019. doi:10.1159/000497404. PMID 31141802.
 |  |
